Market closed
DiaMedica Therapeutics Inc. Common Stock/DMAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About DiaMedica Therapeutics Inc. Common Stock
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Ticker
DMAC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
19
Website
DMAC Metrics
BasicAdvanced
$185M
Market cap
-
P/E ratio
-$0.52
EPS
1.48
Beta
-
Dividend rate
Price and volume
Market cap
$185M
Beta
1.48
52-week high
$4.45
52-week low
$2.05
Average daily volume
58K
Financial strength
Current ratio
17.815
Quick ratio
17.631
Long term debt to equity
0.539
Total debt to equity
0.726
Management effectiveness
Return on assets (TTM)
-23.54%
Return on equity (TTM)
-35.18%
Valuation
Price to book
3.46
Price to tangible book (TTM)
3.46
Price to free cash flow (TTM)
-8.347
Growth
Earnings per share change (TTM)
-15.69%
3-year earnings per share growth (CAGR)
-12.54%
What the Analysts think about DMAC
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for DiaMedica Therapeutics Inc. Common Stock stock.
DMAC Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
DMAC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for DiaMedica Therapeutics Inc. Common Stock stock?
DiaMedica Therapeutics Inc. Common Stock (DMAC) has a market cap of $185M as of October 26, 2024.
What is the P/E ratio for DiaMedica Therapeutics Inc. Common Stock stock?
The price to earnings (P/E) ratio for DiaMedica Therapeutics Inc. Common Stock (DMAC) stock is 0 as of October 26, 2024.
Does DiaMedica Therapeutics Inc. Common Stock stock pay dividends?
No, DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next DiaMedica Therapeutics Inc. Common Stock dividend payment date?
DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders.
What is the beta indicator for DiaMedica Therapeutics Inc. Common Stock?
DiaMedica Therapeutics Inc. Common Stock (DMAC) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.